title: [Review of enteral drugs administration for viral diseases: HIV, HBV and HCV].
abstract: BACKGROUND
  Patients infected with HIV demographic have changed in recent years and sometimes, co-infections with hepatitis virus B and C are common. Due to their longer survival, these patients often present diseases or undergo surgical procedures that preclude the intake of drugs, requiring the use of the enteral administration. This practice, however, may fail due to the lack of adherence, unsuitable drug blood concentrations caused by malabsorption or interactions, and dosage errors. We aim to develop management guidelines for antiviral drugs enteral administration.
  
  
  METHODS
  We reviewed the technical specifications of drugs used in HIV, HBV or HCV. A search was conducted in Pubmed® database and Micromedex®, manufacturers were contacted for futher information and other related literature was reviewed.
  
  
  RESULTS
  The results are shown in table 1.
  
  
  CONCLUSIONS
  Although in pharmaceutical practice crushing tablets is common, sometimes suspension of crushed drugs in water is not completely appropriate for enteral administration, because this practice may alter the bioavailability of drugs, which may modify the therapeutic effect. There is currently not enough evidence that supports the practice of crushed and suspension of drugs exposed in this study. Therefore, the bioavailability of different formulations should be studied more carefully, especially of recent marketing drugs.
authors.forename: José Javier
authors.initials: JJ
authors.lastname: Arenas Villafranca
authors.forename: Miriam
authors.initials: M
authors.lastname: Nieto Guindo
authors.forename: Rocío
authors.initials: R
authors.lastname: Romero Domínguez
authors.forename: Begoña
authors.initials: B
authors.lastname: Tortajada Goitia
authors.forename: Vicente
authors.initials: V
authors.lastname: Faus Felipe
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D003680:Deglutition Disorders / Q000150:complications; D004304:Dosage Forms; D004339:Drug Compounding / Q000379:methods; D005774:Gastrostomy; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007441:Intubation, Gastrointestinal; D012995:Solubility
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D004304:Dosage Forms